JP2021531005A5 - - Google Patents
Info
- Publication number
- JP2021531005A5 JP2021531005A5 JP2021502831A JP2021502831A JP2021531005A5 JP 2021531005 A5 JP2021531005 A5 JP 2021531005A5 JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021531005 A5 JP2021531005 A5 JP 2021531005A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- binding
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023117208A JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700596P | 2018-07-19 | 2018-07-19 | |
| US62/700,596 | 2018-07-19 | ||
| US201862750968P | 2018-10-26 | 2018-10-26 | |
| US62/750,968 | 2018-10-26 | ||
| US201962793645P | 2019-01-17 | 2019-01-17 | |
| US62/793,645 | 2019-01-17 | ||
| PCT/US2019/042447 WO2020018820A1 (en) | 2018-07-19 | 2019-07-18 | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117208A Division JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531005A JP2021531005A (ja) | 2021-11-18 |
| JP2021531005A5 true JP2021531005A5 (enExample) | 2022-07-25 |
| JP7319348B2 JP7319348B2 (ja) | 2023-08-01 |
Family
ID=67515169
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502831A Active JP7319348B2 (ja) | 2018-07-19 | 2019-07-18 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
| JP2023117208A Active JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117208A Active JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Country Status (34)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102546A1 (en) | 2016-11-30 | 2018-06-07 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| IL270894B2 (en) | 2017-06-01 | 2023-04-01 | Regeneron Pharma | Human antibodies to bet v 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| KR20210143246A (ko) * | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| HUE068401T2 (hu) | 2019-11-11 | 2024-12-28 | Amgen Res Munich Gmbh | A BCMA elleni hatóanyagok adagolási rendje |
| JP7693672B2 (ja) * | 2019-12-06 | 2025-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子，其製備方法及醫藥用途 |
| EP4545569A3 (en) * | 2020-06-30 | 2025-10-08 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| US11897945B2 (en) | 2020-07-01 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-Bet v 1 antibodies |
| KR20230069181A (ko) * | 2020-09-14 | 2023-05-18 | 화이자 인코포레이티드 | 암 치료를 위한 방법, 요법 및 용도 |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| JP7905328B2 (ja) | 2020-09-18 | 2026-08-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
| CN118878693A (zh) * | 2020-11-23 | 2024-11-01 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| CN114573703A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种t细胞衔接器治疗剂的开发和应用 |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| TW202246333A (zh) * | 2021-01-20 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途 |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| BR112023027006A2 (pt) * | 2021-06-21 | 2024-03-12 | BioNTech SE | Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação |
| CN120424234A (zh) * | 2021-08-30 | 2025-08-05 | 上海君赛生物科技有限公司 | 含有膜表面结构域的多肽及其用途 |
| EP4428156A4 (en) | 2021-12-03 | 2026-03-04 | Shandong Simcere Biopharmaceutical Co., Ltd. | ANTI-BCMA NANOBODY AND USE THEREOF |
| CA3244028A1 (en) * | 2021-12-22 | 2023-06-29 | The Jackson Laboratory | HUMANIZED WALL MODELS |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN117003871A (zh) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| CA3252182A1 (en) | 2022-05-18 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | MULTISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO CD38 AND 4-1BB AND ASSOCIATED USES |
| WO2023236889A1 (zh) | 2022-06-06 | 2023-12-14 | 山东先声生物制药有限公司 | 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用 |
| AR129560A1 (es) | 2022-06-08 | 2024-09-04 | Tidal Therapeutics Inc | Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos |
| CN115368466A (zh) * | 2022-07-19 | 2022-11-22 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| IL319818A (en) | 2022-10-10 | 2025-05-01 | Regeneron Pharma | Methods for reducing alloantibody levels in patients requiring solid organ transplantation |
| CN117126280B (zh) * | 2022-12-06 | 2024-03-29 | 成都赛恩吉诺生物科技有限公司 | 具有亲水性氨基酸残基的抗人bcma纳米抗体及car-t和应用 |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4725970A1 (en) | 2023-06-06 | 2026-04-15 | Fortvita Biologics Inc. | Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody |
| TW202517293A (zh) | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| EP4777540A1 (en) | 2023-09-13 | 2026-07-22 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN122349420A (zh) | 2023-12-04 | 2026-07-07 | 山东先声再明生物制药有限公司 | 一种多特异性抗体的组合物及其制备方法和应用 |
| WO2025131077A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3多特异性抗体及用途 |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| TW202543581A (zh) | 2024-02-12 | 2025-11-16 | 美商艾伊拉醫療公司 | 遞送組成物 |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202611075A (zh) | 2024-05-13 | 2026-03-16 | 美商再生元醫藥公司 | 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法 |
| WO2025244973A1 (en) | 2024-05-20 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| US20260014252A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof |
| WO2026059920A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| WO2026059917A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
| WO2026059923A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| US20260070998A1 (en) | 2024-09-10 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors |
| US20260158137A1 (en) | 2024-09-10 | 2026-06-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026072557A2 (en) | 2024-09-24 | 2026-04-02 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
| WO2026112559A1 (en) | 2024-11-25 | 2026-05-28 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
| WO2026151982A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HK1043608B (en) | 1999-08-17 | 2007-12-07 | Biogen Ma Inc. | Baff receptor (bcma), an immunoregulatory agent |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| DE10206325A1 (de) | 2002-02-14 | 2003-09-04 | Medinnova Ges Med Innovationen | Ummantelter Mikroorganismus |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| EP2714737A1 (en) | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| US20180112384A1 (en) | 2013-12-30 | 2018-04-26 | Craig Rothleitner | Drainage treatment system |
| BR112016024546A2 (pt) | 2014-04-30 | 2018-01-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| DK3447075T3 (da) | 2015-05-15 | 2023-11-13 | Massachusetts Gen Hospital | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| JP6901493B2 (ja) | 2015-11-13 | 2021-07-14 | アメリカ合衆国 | 抗ｂｃｍａポリペプチド及びタンパク質 |
| ES2913208T3 (es) | 2015-12-01 | 2022-06-01 | Glaxosmithkline Ip Dev Ltd | Tratamientos de combinación y usos y métodos de los mismos |
| JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| MA44254A (fr) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| US12048718B2 (en) | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| EP3481410A2 (en) | 2016-07-08 | 2019-05-15 | Paul C. Tumeh | Compositions and treatment methods for cancer immunotherapy |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| WO2018075359A1 (en) | 2016-10-18 | 2018-04-26 | Boger Henry William | Wireless power transfer for process control |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| EP3572427B1 (en) | 2017-01-23 | 2025-06-25 | CRAGE medical Co., Limited | Bcma-targeting antibody and use thereof |
| WO2018145075A1 (en) | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| MA48763A (fr) | 2017-05-05 | 2020-04-08 | Amgen Inc | Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| UA126813C2 (uk) | 2017-08-01 | 2023-02-08 | Медімм'Юн, Ллк | Моноклональний кон’югат антитіло-лікарський засіб до bcma |
| WO2019066435A2 (ko) | 2017-09-29 | 2019-04-04 | 재단법인 목암생명과학연구소 | Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| CN107827989A (zh) | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
| ES2968880T3 (es) | 2018-02-01 | 2024-05-14 | Nanjing Iaso Biotechnology Co Ltd | Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| KR20210143246A (ko) * | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
-
2019
- 2019-07-17 TW TW108125183A patent/TWI838389B/zh active
- 2019-07-18 HU HUE19749096A patent/HUE070224T2/hu unknown
- 2019-07-18 CN CN201980047976.5A patent/CN112423785B/zh active Active
- 2019-07-18 LT LTEPPCT/US2019/042447T patent/LT3823664T/lt unknown
- 2019-07-18 IL IL279974A patent/IL279974B2/en unknown
- 2019-07-18 JP JP2021502831A patent/JP7319348B2/ja active Active
- 2019-07-18 SG SG11202100252SA patent/SG11202100252SA/en unknown
- 2019-07-18 MA MA53168A patent/MA53168B1/fr unknown
- 2019-07-18 HR HRP20250199TT patent/HRP20250199T1/hr unknown
- 2019-07-18 PL PL19749096.4T patent/PL3823664T3/pl unknown
- 2019-07-18 FI FIEP19749096.4T patent/FI3823664T3/fi active
- 2019-07-18 DK DK19749096.4T patent/DK3823664T3/da active
- 2019-07-18 EP EP24212980.7A patent/EP4516810A3/en active Pending
- 2019-07-18 BR BR112021000186-7A patent/BR112021000186A2/pt unknown
- 2019-07-18 KR KR1020217004615A patent/KR20210034032A/ko active Pending
- 2019-07-18 WO PCT/US2019/042447 patent/WO2020018820A1/en not_active Ceased
- 2019-07-18 SI SI201930882T patent/SI3823664T1/sl unknown
- 2019-07-18 MY MYPI2021000039A patent/MY201816A/en unknown
- 2019-07-18 MD MDE20210483T patent/MD3823664T2/ro unknown
- 2019-07-18 AU AU2019307928A patent/AU2019307928B2/en active Active
- 2019-07-18 MX MX2021000488A patent/MX2021000488A/es unknown
- 2019-07-18 PT PT197490964T patent/PT3823664T/pt unknown
- 2019-07-18 SM SM20250044T patent/SMT202500044T1/it unknown
- 2019-07-18 EP EP19749096.4A patent/EP3823664B1/en active Active
- 2019-07-18 ES ES19749096T patent/ES3010285T3/es active Active
- 2019-07-18 US US16/516,028 patent/US11384153B2/en active Active
- 2019-07-18 RS RS20250180A patent/RS66535B1/sr unknown
-
2021
- 2021-01-06 ZA ZA2021/00087A patent/ZA202100087B/en unknown
- 2021-01-06 PH PH12021550031A patent/PH12021550031A1/en unknown
- 2021-01-13 CO CONC2021/0000188A patent/CO2021000188A2/es unknown
- 2021-01-13 MX MX2025005515A patent/MX2025005515A/es unknown
- 2021-01-15 CL CL2021000131A patent/CL2021000131A1/es unknown
-
2022
- 2022-05-31 US US17/828,847 patent/US12258412B2/en active Active
-
2023
- 2023-07-19 JP JP2023117208A patent/JP7586974B2/ja active Active
-
2025
- 2025-02-19 US US19/057,229 patent/US20260008862A1/en active Pending
- 2025-04-04 CY CY20251100235T patent/CY1127721T1/el unknown
- 2025-07-08 LT LTPA2025526C patent/LTPA2025526I1/lt unknown
- 2025-07-14 NL NL301335C patent/NL301335I2/nl unknown
- 2025-07-16 CY CY2025020C patent/CY2025020I1/el unknown
- 2025-07-29 FR FR25C1029C patent/FR25C1029I2/fr active Active
- 2025-08-05 HU HUS2500032C patent/HUS2500032I1/hu unknown
- 2025-08-07 NO NO2025036C patent/NO2025036I1/no unknown
- 2025-08-14 FI FIC20253006C patent/FIC20253006I1/fi unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3823664T3 (fi) | Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä | |
| CN107405397B (zh) | 抗tim-3抗体 | |
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2023543152A5 (enExample) | ||
| JP2022515611A5 (enExample) | ||
| KR102838340B1 (ko) | 다중-특이적 항체 및 이들의 제조 및 사용 방법 | |
| JP2021527431A5 (enExample) | ||
| AU2023203119A1 (en) | Cd20 binding molecules and uses thereof | |
| JP2023505218A5 (enExample) | ||
| JP2021506244A5 (enExample) | ||
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2020528750A5 (enExample) | ||
| HRP20160009T1 (hr) | Protutijela anti-cd37 | |
| KR20170102167A (ko) | 항-pd-l1 항체 | |
| JP2022533538A5 (enExample) | ||
| EP3341020A1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| JP2020537520A (ja) | Ｃｄ１３７を標的とする抗体とその利用方法 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022514734A5 (enExample) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| JP2024540148A5 (enExample) | ||
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |